Fig. 5From: Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systemsDecision curve analysis. a, b PCa and csPCa scores in the development cohort. c, d PCa and csPCa scores in the validation cohort. The blue line (Net Benefit: Treat All) was the hypothesis that all patients had PCa and csPCa and the red line (Net Benefit: Treat None) which parallel to the horizontal axis was the hypothesis that no patients had PCa and csPCaBack to article page